选择性增殖腺病毒ONYX3-015及其治疗对肿瘤患者生活质量的影响(英文) 被引量：2

Replication-selective adenovirus ONYX-015:a new anti-tumor drug for improving the patients' quality of life

下载PDF

导出

摘要选择性增殖腺病毒dl1520是一种新型的进入III期临床研究的肿瘤病毒基因治疗药物,本文综述了dl1520的发现、结构、实验研究和作用机制、临床试验研究疗效以及研究方向和展望,提倡使用此种肿瘤基因药物在肿瘤患者治疗及预后生存期内减少毒副反应,希望可以在提高患者生存质量上提供理论依据。 Replication-selective adenovirus ONYX-015 is a new drug in viral gene therap y against tumor. We reviewed its discovery, structure, experimental study and cl inical trial results,hoping to provide theoretical bases for its eventual clinic al application in tumor patients,to improve their prognosis and reduce adverse e ffect during the therapy and ultimately,to help the patients have better quality of life.

作者聂飚

机构地区解放军第一军医大学珠江医院检验科

出处《中国临床康复》 CSCD 2003年第26期3580-3581,共2页 Chinese Journal of Clinical Rehabilitation

关键词肿瘤基因治疗选择性增殖腺病毒 dl1520

分类号 R730.54 [医药卫生—肿瘤]

引文网络
相关文献

参考文献13

1RG Vile, SJ Russell and NR Lemoine. Cancer gene therapy: hard lessons and new courses. Gene Therapy 2000; 7:2 -8.
2Douglas D. bar]her and Arnold J. berk. Adenovirus proteins from both E1B reading frames are repuired for tramforumtion of rodent cells by viral infection and DNA tramfection. Virology 1987; 156:107 -21.
3James B. Biechoff, David Kirn, Angelica Willisms, et al. An adenovirus mutant that replicates selectively in p53- deficient human tumor cells. Science 1997; 274(5286) : 373.
4Hall AR, Dix BB, O' Carroll SJ et al. PS3-dependent cell death/apoptosis is requbed for a productive adenovirus infection. Nature Meadicine 1998, 4(9): 1068 -72.
5Ganiy I, Eckhardt SG, Bodriguez GI, Soutar DS. A phase I study of Onyx-015, an E1B attenuated adenovlrus, administered intratumondly to patients with vecureent head and neck cancer. C linical Cancer Research 2000; 6(3): 798 - 806.
6Zhao J, Wang H, Wei L, et al. The cytotoxic effect of E1B 55-kDa mutant adenovirus on human hepatocellular carcinoma cell lines. Cancer Gene Ther 2001;8(5):333 -41.
7Dix BB, O' Carroll SJ, Myers C J, et al. Efficient induction of cell death by adenobiruses requires binding of E1B-55K and p53. Cancer Research 2000; 60(10):2666 - 72.
8Kirn D. Clinical research results with ONYX-015 (Onyx-015), a replication -selective adenovlrus for the weatmertt of cancer: what have we learned? Gene Ther 2001:8(2):89-98.
9MulvihiU S, Warren R, Venook A, et al. Safety and feasibility of injection with an E1B-55 kDa gone-deleted, replication-selective adenovirus (ONYX-015) into primary carcinomas of the pancreas: a phase Ⅰ trial. Gene Ther 2001 ; 8(4):308 -15.
10Nemunaitis J, Cunningham C, Buchanan A, et al. Intravenous infusion of a replication-selective adenovirus (ONYX-015) in cancer patients: safety, feasibility and biological activity. Gene Ther 2001; 8(10): 746 - 59.